Table 3.
Univariate and multivariate Cox regression analyses of NCAPH mRNA expression for overall survival (OS) in patients with LUAD from The Cancer Genome Atlas (TCGA) data set.
| Characteristics | Total (N) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
| T stage | 523 | ||||
| T1 | 175 | Reference | |||
| T2 | 282 | 1.521 (1.068–2.166) | 0.020 | 1.356 (0.822–2.236) | 0.233 |
| T3&T4 | 66 | 3.066 (1.950–4.823) | < 0.001 | 2.192 (1.077–4.458) | 0.030 |
| N stage | 510 | ||||
| N0 | 343 | Reference | |||
| N1 | 94 | 2.382 (1.695–3.346) | < 0.001 | 1.750 (1.096–2.793) | 0.019 |
| N2&N3 | 73 | 2.968 (2.040–4.318) | < 0.001 | 2.502 (1.017–6.153) | 0.046 |
| M stage | 377 | ||||
| M0 | 352 | Reference | |||
| M1 | 25 | 2.136 (1.248–3.653) | 0.006 | 1.631 (0.623–4.266) | 0.319 |
| Pathologic stage | 518 | ||||
| Stage I&Stage II | 411 | Reference | |||
| Stage III&Stage IV | 107 | 2.664 (1.960–3.621) | < 0.001 | 1.006 (0.400–2.531) | 0.990 |
| Primary therapy outcome | 439 | ||||
| PD&SD | 108 | 2.653(3.731–1.887) | < 0.001 | 2.778(1.821–4.219) | < 0.001 |
| PR&CR | 331 | Reference | |||
| Gender | 526 | ||||
| Female | 280 | Reference | |||
| Male | 246 | 1.070 (0.803–1.426) | 0.642 | ||
| Smoker | 512 | ||||
| Yes | 440 | Reference | |||
| No | 72 | 1.119 (0.742–1.688) | 0.591 | ||
| NCAPH | 526 | ||||
| Low | 263 | Reference | |||
| High | 263 | 1.92 (1.37–2.70) | < 0.001 | 1.347 (0.898–2.019) | 0.150 |
Significant values are in bold.